Abstract
Given the narrowness of the initial testing criteria, the SARS-CoV-2 virus spread through cryptic transmission in January and February, setting the stage for the epidemic wave experienced in March and April, 2020. We use a global metapopulation epidemic model to provide a mechanistic understanding of the global dynamic underlying the establishment of the COVID-19 pandemic in Europe and the United States (US). The model is calibrated on international case introductions at the early stage of the pandemic. We find that widespread community transmission of SARS-CoV-2 was likely in several areas of Europe and the US by January 2020, and estimate that by early March, only 1 − 3 in 100 SARS-CoV-2 infections were detected by surveillance systems. Modeling results indicate international travel as the key driver of the introduction of SARS-CoV-2 with possible importation and transmission events as early as December, 2019. We characterize the resulting heterogeneous spatio-temporal spread of SARS-CoV-2 and the burden of the first COVID-19 wave (February-July 2020). We estimate infection attack rates ranging from 0.78%-15.2% in the US and 0.19%-13.2% in Europe. The spatial modeling of SARS-CoV-2 introductions and spreading provides insights into the design of innovative, model-driven surveillance systems and preparedness plans that have a broader initial capacity and indication for testing.
Competing Interest Statement
M.E.H. reports grants from National Institute of General Medical Sciences, during the conduct of the study; M.A. reports research funding from Seqirus, not related to COVID-19. A.V., M.C. and A.P.P. report grants from Metabiota inc., outside the submitted work. No other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
A.V., M.E.H., N.E.D., and I.M.L acknowledge support from NIH-R56AI148284 award. S.M. acknowledges support from the EU H2020 MOOD project. C.G. and L.R. acknowledge support from the EU H2020 Icarus project. M.A., M.C.and A.V. acknowledge support from COVID Supplement CDC-HHS-6U01IP001137-01. M.C. and A.V. acknowledge support from Google Cloud and Google Cloud Research Credits program to fund this project. A.V. acknowledges support from the McGovern and the Chleck Foundation. The findings and conclusions in this study are those of the authors and do not necessarily represent the official position of the funding agencies, the National Institutes of Health, or the U.S. Department of Health and Human Services.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Proprietary airline data are commercially available from Official Aviation Guide (OAG) and IATA databases. The GLEAM model is publicly available at http://www.gleamviz.org/.
